A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
Study Summary
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
Lead SponsorMorphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Data Retrieved2026-04-11 02:55:33.867149+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.